The stock of Aratana Therapeutics Inc (NASDAQ:PETX) is a huge mover today! About 312,562 shares traded hands. Aratana Therapeutics Inc (NASDAQ:PETX) has risen 127.17% since March 8, 2016 and is uptrending. It has outperformed by 117.85% the S&P500.
The move comes after 6 months negative chart setup for the $339.31M company. It was reported on Oct, 11 by Barchart.com. We have $7.95 PT which if reached, will make NASDAQ:PETX worth $47.50M less.
Analysts await Aratana Therapeutics Inc (NASDAQ:PETX) to report earnings on November, 3. They expect $-0.44 EPS, down 37.50% or $0.12 from last year’s $-0.32 per share. After $0.69 actual EPS reported by Aratana Therapeutics Inc for the previous quarter, Wall Street now forecasts -163.77% negative EPS growth.
Aratana Therapeutics Inc (NASDAQ:PETX) Ratings Coverage
Out of 6 analysts covering Aratana Therapeutics (NASDAQ:PETX), 5 rate it a “Buy”, 0 “Sell”, while 1 “Hold”. This means 83% are positive. Aratana Therapeutics has been the topic of 9 analyst reports since July 29, 2015 according to StockzIntelligence Inc. The firm has “Buy” rating given on Wednesday, March 16 by Stifel Nicolaus. Barclays Capital maintained Aratana Therapeutics Inc (NASDAQ:PETX) on Thursday, August 11 with “Overweight” rating. Credit Suisse initiated the stock with “Outperform” rating in Thursday, February 4 report. Jefferies initiated Aratana Therapeutics Inc (NASDAQ:PETX) on Friday, August 19 with “Buy” rating. The rating was initiated by Lake Street on Wednesday, July 29 with “Buy”. The firm has “Hold” rating by Craig Hallum given on Friday, September 25.
According to Zacks Investment Research, “Aratana Therapeutics Inc. is a biopharmaceutical company for animals. The Company is developing compounds for the pet health market, including a non-COXIB analgesic for treating pain, an appetite-stimulating molecule for inappetence and licensed non-opioid local anesthetic for treating post-operative pain. It operates in the United States and Europe. Aratana Therapeutics Inc. is headquartered in Kansas City, Kansas.”
Insitutional Activity: The institutional sentiment increased to 1.59 in Q2 2016. Its up 0.47, from 1.12 in 2016Q1. The ratio increased, as 11 funds sold all Aratana Therapeutics Inc shares owned while 21 reduced positions. 12 funds bought stakes while 39 increased positions. They now own 30.25 million shares or 0.77% less from 30.49 million shares in 2016Q1.
Woodstock last reported 39,344 shares in the company. March Altus Cap Mngmt Ltd Partnership owns 218,515 shares or 10.67% of their US portfolio. Moreover, Jennison Associates Ltd Co has 0.02% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 2.86M shares. Moreover, Deere has 0.02% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 63,980 shares. Manufacturers Life Ins Company The holds 241,005 shares or 0% of its portfolio. Hamilton Lane Limited Co holds 0.39% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX) for 111,705 shares. Westend Ltd Liability has 0.68% invested in the company for 73,900 shares. Mariner Wealth Ltd Liability Corporation holds 0.02% or 51,773 shares in its portfolio. Metropolitan Life Insurance Ny last reported 25,709 shares in the company. Northern Tru Corporation holds 0% or 356,862 shares in its portfolio. Continental Advisors Limited Liability holds 124,399 shares or 0.24% of its portfolio. Vanguard Group Inc holds 1.27 million shares or 0% of its portfolio. Broadfin Ltd last reported 3.43M shares in the company. Moreover, Weiss Multi has 0.03% invested in Aratana Therapeutics Inc (NASDAQ:PETX) for 61,965 shares. Turner Investments L P holds 0.72% of its portfolio in Aratana Therapeutics Inc (NASDAQ:PETX) for 361,990 shares.
Insider Transactions: Since June 10, 2016, the stock had 0 insider purchases, and 5 sales for $1.57 million net activity. 15,000 shares were sold by HEINEN ERNST, worth $100,862. 50,000 Aratana Therapeutics Inc (NASDAQ:PETX) shares with value of $462,500 were sold by St Peter Steven. On Friday, September 9 TOOMAN CRAIG A sold $277,599 worth of the stock or 30,000 shares.
More notable recent Aratana Therapeutics Inc (NASDAQ:PETX) news were published by: Fool.com which released: “How Aratana Therapeutics Inc. Clawed Its Way to a 17% Gain in August” on September 09, 2016, also Prnewswire.com with their article: “Aratana Therapeutics to Participate in Jefferies Animal Health Leadership Summit” published on September 21, 2016, Prnewswire.com published: “Aratana Therapeutics Files for FDA Approval of NOCITA® (bupivacaine liposome …” on June 30, 2016. More interesting news about Aratana Therapeutics Inc (NASDAQ:PETX) were released by: Prnewswire.com and their article: “Aratana Therapeutics Files for Second FDA Approval” published on March 22, 2016 as well as Prnewswire.com‘s news article titled: “Aratana Therapeutics to Present GALLIPRANT® (grapiprant tablets) Pivotal Data” with publication date: March 31, 2016.
PETX Company Profile
Aratana Therapeutics, Inc., incorporated on December 1, 2010, is a pet therapeutics firm focused on licensing, developing and commercializing of biopharmaceutical products for companion animals. The Company’s portfolio includes therapeutic candidates in development consisting of small molecule pharmaceuticals and large molecule biologics that target medical conditions in pets. The Company’s lead product candidates in development include small molecules directed at treating osteoarthritis pain and inflammation (AT-001 for dogs, also known as grapiprant for dogs or GALLIPRANT), appetite stimulation (AT-002 for dogs, also known as capromorelin for dogs or ENTYCE) and post-operative pain (AT-003 for dogs, also known as bupivacaine liposome injectable suspension for dogs or NOCITA). The Company’s product candidates also include AT-014 for dogs.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.